- Heidi Hunter, accomplished healthcare leader and President of Cardinal Health Specialty Solutions, to bring additional global biopharma strategic and operational expertise to Sutro's Board - SOUTH SAN FRANCISCO, Nov. 17,2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...
- Patient enrollment has been completed for the STRO-002 Phase 1 ovarian cancer dose-expansion cohort, and an interim data update is expected in the second half of 2021 – - STRO-001 Phase 1 dose escalation for non-Hodgkin’s lymphoma and multiple myeloma is ongoing to...
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
SOUTH SAN FRANCISCO and SHANGHAI, China, Oct. 12, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer...
- Nicole M. Chieffo, MBA, appointed to Vice President of Clinical Operations - Werner Rubas, Ph.D., appointed to Vice President of Preclinical Development SOUTH SAN FRANCISCO, Calif., Sept. 16, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug...
SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
SOUTH SAN FRANCISCO, August 18, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
- Additional follow-up data on STRO-002 from the Phase 1 dose-escalation cohort were presented at ASCO June 2021; enrollment for the Phase 1 dose-expansion cohort is ongoing - Milestone payment earned from Merck for initiation of IND-enabling study and from EMD...
Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Aug. 9, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein...
